GDRX

GoodRx Holdings Inc

Add to Watchlist

Advanced Chart

4.890

+0.02(0.411%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.000

Open

4.860

VWAP

Vol

854.25K

Mkt Cap

1.75B

Low

4.8401

Amount

EV/EBITDA(TTM)

11.55

Total Shares

375.33M

1.93B

EV/OCF(TTM)

12.80

P/S(TTM)

2.35

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordability solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

207.40M

+4.44%

204.85M

+4.92%

205.55M

+2.46%

Estimates Revision

The market is revising No Change the revenue expectations for GoodRx Holdings, Inc. (GDRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 5.62%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+5.62%

In Past 3 Month

12 Analyst Rating

29.65% Upside

Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 6.34 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

4 Hold

1 Sell

Moderate Buy

29.65% Upside

Current: 4.890

Low

4.00

Averages

6.34

High

9.00

29.65% Upside

Current: 4.890

Low

4.00

Averages

6.34

High

9.00

UBS

Neutral

downgrade

2025-05-13

Reason

UBS

Price Target

2025-05-13

downgrade

Neutral

Reason

UBS lowered the firm's price target on GoodRx to $5.25 from $6 and keeps a Neutral rating on the shares.

BofA

Allen Lutz

Underperform

downgrade

2025-05-08

Reason

BofA

Allen Lutz

Price Target

2025-05-08

downgrade

Underperform

Reason

BofA analyst Allen Lutz lowered the firm's price target on GoodRx to $4 from $4.75 and keeps an Underperform rating on the shares. GoodRx reported "a mixed, but generally good headline quarter," beating on both revenue and EBITDA, the analyst tells investors. However, the firm lowered its price target ahead of the earnings call as it lowered its calendar year 2025 EBITDA multiple to reflect lower top-line momentum.

Truist Securities

Jailendra Singh

Hold

Maintains

$6.5 → $5.5

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$6.5 → $5.5

2025-04-10

Maintains

Hold

Reason

Truist lowered the firm's price target on GoodRx to $5.50 from $6.50 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in the Healthcare IT industry. The industry is typically shielded from macro uncertainty, but tariffs and concerns around an economic slowdown have created broader market uncertainty, which is never good for a high-beta highly volatile group like HCIT/Digital Health/Payviders, the analyst tells investors in a research note. Truist adds that while HCIT companies may not be directly exposed to new tariffs, several of these companies serve end markets - hospitals, pharma, etc. - which are likely to see either some direct impact on their supply chain costs or could decide to slow down on their investments.

Wells Fargo

Stan Berenshteyn

Buy

Maintains

$9 → $8

2025-02-28

Reason

Wells Fargo

Stan Berenshteyn

Price Target

$9 → $8

2025-02-28

Maintains

Buy

Reason

Citigroup

Daniel Grosslight

Strong Buy

Maintains

$7 → $6.25

2025-01-10

Reason

Citigroup

Daniel Grosslight

Price Target

$7 → $6.25

2025-01-10

Maintains

Strong Buy

Reason

Citi analyst Daniel Grosslight lowered the firm's price target on GoodRx to $6.25 from $7 and keeps a Buy rating on the shares as part of a 2025 outcook for the health technology and distribution group. The firm says that while 2024 was another difficult year for health tech stocks, rather than being driven by deteriorating fundamentals, much of the selloff was due to continued multiple compression, which signals "we have likely reached a valuation floor." Looking ahead to 2025, Citi is "cautiously optimistic" on the health tech space, saying there seems to be a bit of a post-election risk bid, acquisition activity has accelerated, and expectations have been sufficiently reset. Citi names Health Catalyst (HCAT) its top health tech pick and Cencora (COR) its top distribution pick.

Keybanc

Scott Schoenhaus

Buy

Maintains

$7 → $6

2025-01-08

Reason

Keybanc

Scott Schoenhaus

Price Target

$7 → $6

2025-01-08

Maintains

Buy

Reason

KeyBanc lowered the firm's price target on GoodRx to $6 from $7 and keeps an Overweight rating on the shares. The firm notes healthcare technology stocks were under pressure for most of last year but saw a rebound in the last two months following the Trump election. In combination with consensus estimate cuts since the middle of last year, KeyBanc sees attractive buying opportunities in the space in 2025. From a valuation multiple perspective, the firm believes companies with healthy balance sheets and steady free cash flow profiles will see less risk to multiple contraction, even with more modest growth trends. Conversely, it sees the most risk for companies that have challenged balance sheets and limited profitability in the near and longer term.

See All Ratings

Valuation Metrics

The current forward P/E ratio for GoodRx Holdings Inc (GDRX.O) is 28.71, compared to its 5-year average forward P/E of 111.56. For a more detailed relative valuation and DCF analysis to assess GoodRx Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

111.56

Current PE

28.71

Overvalued PE

770.92

Undervalued PE

-547.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

26.70

Current EV/EBITDA

7.57

Overvalued EV/EBITDA

52.48

Undervalued EV/EBITDA

0.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.09

Current PS

2.29

Overvalued PS

16.19

Undervalued PS

-0.01

Financials

Annual

Quarterly

FY2025Q1

YoY :

+2.57%

202.97M

Total Revenue

FY2025Q1

YoY :

+20.53%

24.63M

Operating Profit

FY2025Q1

YoY :

-1195.34%

11.05M

Net Income after Tax

FY2025Q1

0.03

EPS - Diluted

FY2025Q1

YoY :

-156.72%

-12.46M

Free Cash Flow

FY2025Q1

YoY :

-2.95%

83.11

Gross Profit Margin - %

FY2025Q1

YoY :

-12.37%

9.92

FCF Margin - %

FY2025Q1

YoY :

-1168.63%

5.45

Net Margin - %

FY2025Q1

9.34

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

94.9K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

618.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 1160% over the last quarter.

Sold

0-3

Months

126.0M

Volume

3-6

Months

10.0M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

2.3M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

94.9K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

618.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

GDRX News & Events

Events Timeline

2025-06-11 (ET)

2025-06-11

06:05:21

GoodRx ED offering meant to compete with Hims & Hers, says Citi

2025-06-10 (ET)

2025-06-10

09:09:22

GoodRx launches new subscription service for erectile dysfunction

2025-05-07 (ET)

2025-05-07

16:16:52

GoodRx backs FY25 revenue view $810M-$840M, consensus $823.27M

News

5.0

07-28Newsfilter

GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

5.0

06-10Newsfilter

GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers

5.0

06-10SeekingAlpha

GoodRx launches new subscription service focused on erectile dysfunction treatments

People Also Watch

BIO.B

Bio Rad Laboratories Inc

Aris Water Solutions Inc

eXp World Holdings Inc

Star Bulk Carriers Corp

Benchmark Electronics Inc

Ultra Clean Holdings Inc

Amphastar Pharmaceuticals Inc

FAQ

What is GoodRx Holdings Inc (GDRX) stock price today?

The current price of GDRX is 4.89 USD — it has increased 0.41 % in the last trading day.

GDRX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

GDRX News & Events

Events Timeline

News

People Also Watch

FAQ

What is GoodRx Holdings Inc (GDRX) stock price today?

What is GoodRx Holdings Inc (GDRX)'s business?

What is the price predicton of GDRX Stock?

What is GoodRx Holdings Inc (GDRX)'s revenue for the last quarter?

What is GoodRx Holdings Inc (GDRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for GoodRx Holdings Inc (GDRX)'s fundamentals?

How many employees does GoodRx Holdings Inc (GDRX). have?

What is GoodRx Holdings Inc (GDRX) market cap?